Water pill could boost kidney Drug's power and cut side effects

NCT ID NCT05373264

Recruiting now Disease control Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests whether adding a common water pill (hydrochlorothiazide) to the standard drug tolvaptan can slow kidney function decline and reduce side effects like frequent urination in people with autosomal dominant polycystic kidney disease (ADPKD). About 300 adults on a stable dose of tolvaptan will receive either hydrochlorothiazide or a placebo. The goal is to improve both treatment effectiveness and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease Polyuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADPKD

Contacts and locations

Locations

Amsterdam University Medical Center
RECRUITING

Amsterdam, Netherlands
Centre Hôpital Universitaire de Lyon
RECRUITING

Lyon, France
Charité University Hospital
RECRUITING

Berlin, Germany
Cliniques Universitaires Saint-Luc
RECRUITING

Brussels, Belgium
Erasmus University Medical Center
RECRUITING

Rotterdam, Netherlands
Fundación Puigvert
RECRUITING

Barcelona, Spain
Hospital La Cavale Blanche
RECRUITING

Brest, France
Hospital Universitario Mancha Centro
RECRUITING

Alcázar de San Juan, Spain
Hospital Universitario Vall D'Hebron
RECRUITING

Barcelona, Spain
Hôpital Fribourgeois (HFR)
RECRUITING

Fribourg, Switzerland
Hôpital Pellegrin (CHU Bordeaux)
RECRUITING

Bordeaux, France
Hôpitaux Universitaires de Genève (HUG)
RECRUITING

Geneva, Switzerland
Hôpitaux de Brabois (CHRU)
RECRUITING

Nancy, France
La Fundación Jiménez Díaz
RECRUITING

Madrid, Spain
Med. Klinik und Poliklinik III, Universitätsklinikum Dresden.
RECRUITING

Dresden, Germany
Necker-Enfants Malades Hospital
RECRUITING

Paris, France
Universitair Ziekenhuis Antwerpen (UZA)
RECRUITING

Antwerp, Belgium
University Hospital Cologne
RECRUITING

Cologne, Germany
University Hospital Leuven
RECRUITING

Leuven, Belgium
University Medical Center Groningen
RECRUITING

Groningen, Netherlands
Universitätsspital Bern (Inselsspital)
RECRUITING

Bern, Switzerland
Universitätsspital Zürich (USZ)
RECRUITING

Zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.